The first and only mission-driven,
self-sustaining, scalable venture philanthropy
fund focused on multiple myeloma.
Expanding on over 25 years of experience and impact, the Multiple Myeloma Research Foundation (MMRF) launched the Myeloma Investment Fund (MIF) in 2019 as a venture philanthropy fund. With a goal of growing to over $50M, the MIF will focus on advancing the MMRF’s mission to accelerate a cure for each and every multiple myeloma patient. The MIF will invest in the most promising companies, technology platforms, and assets that have the potential to bring transformative new medicines to myeloma patients. In addition to financial support, the MIF offers prospective companies strategic guidance and insights through our robust molecular and longitudinal clinical data sets, extensive network of leading academic medical centers and investigators, as well as internal scientific and clinical expertise.
Our aim is to create major scientific breakthroughs by directing capital where financial support and strategic partnership could have an immediate and meaningful impact on patients’ lives. As a venture philanthropy fund, neither management nor donors to the Myeloma Investment Fund receive distributions. All profits are recycled back into the MIF, allowing us to continually invest in emerging science and companies.